ranolazine
Generic: ranolazine
Labeler: micro labs limitedDrug Facts
Product Profile
Brand Name
ranolazine
Generic Name
ranolazine
Labeler
micro labs limited
Dosage Form
TABLET, EXTENDED RELEASE
Routes
Active Ingredients
ranolazine 1000 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
42571-325
Product ID
42571-325_d172a3c8-ae0a-9ccb-e053-2a95a90a069e
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA211745
Listing Expiration
2026-12-31
Marketing Start
2020-06-01
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
42571325
Hyphenated Format
42571-325
Supplemental Identifiers
RxCUI
UPC
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
ranolazine (source: ndc)
Generic Name
ranolazine (source: ndc)
Application Number
ANDA211745 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 1000 mg/1
Packaging
- 100 BLISTER PACK in 1 CARTON (42571-325-11) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (42571-325-32)
- 60 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-325-60)
- 180 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-325-64)
Packages (3)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "d172a3c8-ae0a-9ccb-e053-2a95a90a069e", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "upc": ["0342571324605", "0342571325602"], "unii": ["A6IEZ5M406"], "rxcui": ["616749", "728231"], "spl_set_id": ["f6facddc-c020-436e-8e68-bf9a4223e7cf"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["Micro Labs Limited"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "100 BLISTER PACK in 1 CARTON (42571-325-11) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (42571-325-32)", "package_ndc": "42571-325-11", "marketing_start_date": "20200601"}, {"sample": false, "description": "60 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-325-60)", "package_ndc": "42571-325-60", "marketing_start_date": "20200601"}, {"sample": false, "description": "180 TABLET, EXTENDED RELEASE in 1 BOTTLE (42571-325-64)", "package_ndc": "42571-325-64", "marketing_start_date": "20200601"}], "brand_name": "Ranolazine", "product_id": "42571-325_d172a3c8-ae0a-9ccb-e053-2a95a90a069e", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "42571-325", "generic_name": "Ranolazine", "labeler_name": "Micro Labs Limited", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Ranolazine", "active_ingredients": [{"name": "RANOLAZINE", "strength": "1000 mg/1"}], "application_number": "ANDA211745", "marketing_category": "ANDA", "marketing_start_date": "20200601", "listing_expiration_date": "20261231"}